secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2025-01-02T23:59:59+00:00
Accession:  0001477932-25-000006
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus Gene Lab gets Nasdaq extension to May 1, 2025 for bid price compliance; plans reverse split
--------------------------------------------------------------------------------

- Nasdaq Hearings Panel grants temporary exception until May 1, 2025 to regain minimum $1.00 bid price.
- Company intends to effect a reverse stock split by April 7, 2025 if needed.
- Effective Jan 30, 2025, Nasdaq requires 10-day prior notice of reverse split details, including shareholder approval date.
- Failure to comply by May 1, 2025 will result in delisting from Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793225000006/0001477932-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793225000006/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer